Sermorelin for sale USA is a filter, not a question, and the filter exists for four reasons that buyers rarely separate. Three are practical and one is regulatory, and the regulatory one is the least understood of the four because sermorelin's position in the United States is genuinely different from the compounds sold beside it. This page takes the practical case first and then the legal picture, which turns out to be more favourable than most competing pages report.
Key takeaways
- Domestic dispatch removes a border, which removes seizure risk, several transit days and a stretch of the journey nobody is monitoring for temperature.
- Recourse is the underrated half. A US business with written terms and a reversible payment rail gives a failed order a remedy; an overseas parcel gives it a tracking number.
- Sermorelin's US regulatory position is unusually good. It was approved as Geref, NDA 019863 and NDA 020443, and is discontinued with the FDA record stating the withdrawal was not for safety or effectiveness reasons.
- It is absent from FDA's Category 2 bulk substances list in every section, while ibutamoren mesylate is listed under both 503A and 503B and ipamorelin acetate, GHRP-2 and GHRP-6 are listed as well. That absence is why a 503A compounding route exists.
- Research-use labelling is a statement about the transaction, not a verdict on the molecule. It means the seller makes no human-use claim, and it does not mean the compound is prohibited.
The vendor we point lifters to
Sermorelin from Ascension Peptides
Independently assayed material, dispatched from the US. The vial drops by half with the code below.
The published certificate for lot 38-01260229 assays this vial at 11.31 mg against a 10 mg label, and reports purity and quantity only, with no endotoxin or sterility testing. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.
- Lot certificate published, purity and quantity
- Free delivery above $250
- Same-day dispatch on orders before 2pm CST
Research material, laboratory use only, not for human consumption. Affiliate links: we may earn a commission at no extra cost to you. Pricing verified September 6, 2026.
Sermorelin for sale USA: what the border actually costs
| Risk | Imported order | Domestic dispatch |
|---|---|---|
| Customs | Inspection, delay, possible seizure with no remedy | Not in the path at all |
| Transit days | Often weeks, unpredictable | Typically two to five days |
| Temperature exposure | Cumulative, unmonitored, worse in summer | Short and largely known |
| Refunds | Depends on a seller in another jurisdiction | Written terms, enforceable in practice |
| Payment recourse | Frequently an irreversible rail | Card or ACH dispute available |
| Identity of the seller | Often unclear | A named entity with an address |
Only the first row is about law. The other five are about what happens to a parcel and to your money, and in aggregate they matter more to the average buyer than the regulatory question does.
Heat, time, and a freeze-dried powder
Lyophilised peptide is a robust shipping format. It exists precisely so that material can survive a journey a reconstituted solution could not. Robust is not the same as indifferent.
Two variables accumulate. The first is time, because every additional day is another day at whatever ambient temperature the parcel is sitting in, and a shipment that spends a weekend in a sorting facility in August has had a different journey from one delivered in two days in March. The second is the border itself, which adds unpredictable days in conditions nobody is measuring.
Domestic dispatch collapses both. A stated warehouse and a published order cutoff turn transit from a variable into a number you can check against a tracking record, which is the whole practical case for the USA filter. The arrival-side checks that follow from this are set out on our online ordering page.
Recourse is the half nobody shops for
Buyers compare prices before an order and compare policies only after something goes wrong, which is the wrong order.
A domestic transaction gives a failed order three things: a named business entity, written terms on non-delivery and damage, and a payment rail that can be reversed without the seller's cooperation. An international transaction with an irreversible rail gives it none of those. The saving on the sticker rarely covers the difference, because the difference is the entire value of the order when it fails.
This is also why a checkout that accepts only irreversible payment is a signal worth reading. It is not proof of anything, but it tells you what the seller expects disputes to look like.
The US regulatory picture, which is better than you have read
Here is where sermorelin separates from almost everything sold alongside it, and where a lot of competing pages are simply wrong.
Sermorelin was an approved drug in the United States. EMD Serono held it as Geref under two applications: NDA 019863, the diagnostic presentation at 0.05 mg per ampoule with submissions from May 1991, and NDA 020443, the therapeutic presentation at 0.5 mg and 1 mg per vial, originally approved on September 26, 1997. Both are listed as discontinued in Drugs@FDA, and the product record carries the Federal Register determination that the product was not discontinued or withdrawn for safety or effectiveness reasons. This was a commercial exit. DailyMed returns no current label because nothing is being marketed.
That history has a live consequence. Under section 503A a compounder may work with a bulk drug substance that is a component of an FDA-approved drug product, even where no USP monograph exists. Sermorelin acetate was exactly that, so the compounding route never depended on a nomination to any list.
Which is why the absence is meaningful. Sermorelin does not appear on FDA's Category 2 bulk substances list in any section, active or withdrawn. Ibutamoren mesylate does, under both 503A and 503B. Ipamorelin acetate is listed under 503B, as are GHRP-2 and GHRP-6. Kisspeptin-10 is listed under 503A. BPC-157, Melanotan II, Selank, Semax, MOTS-c and epitalon were nominated and then withdrawn. Sermorelin is in none of those places, and the prescription route that follows is described on our prescription page.
What "research use only" does and does not mean
This phrase causes more confusion than any other on a domestic listing, so it is worth separating carefully.
What it means: the seller is making no human-use claim, publishes no dosing, and is selling the material for laboratory purposes. That is a statement about the terms of the transaction and about what the seller is permitted to say without a label behind the product.
What it does not mean: that the compound is prohibited, that it was pulled for safety, or that no legitimate route exists. All three of those are false for sermorelin specifically, and repeating them is how competing pages end up misinforming readers in the direction of alarm.
There is a corollary that cuts the other way. Because the seller is not permitted to make human-use claims, a listing that publishes a dosing chart or an outcome promise has not become more helpful, it has stepped outside the terms it operates under. That is a poor signal about how carefully the same operation handles lot control and cold chain.
What domestic stock still cannot fix
Faster shipping does not change the compound or the evidence, and on a site read by people who train, that belongs in the body rather than in a footnote.
Sermorelin is a secretagogue: a synthetic twenty-nine amino acid peptide identical to the active N-terminal fragment of growth hormone releasing hormone, which binds the GHRH receptor on the anterior pituitary and prompts release of the body's own growth hormone. It is not HGH.
The approved indications behind the Geref applications were paediatric growth hormone deficiency and pituitary diagnostics. PubMed returns 332 papers mentioning sermorelin, three with it in the title, and zero for sermorelin and anti-aging. ClinicalTrials.gov registers no studies naming the compound. The two title papers worth knowing about are a 1999 BioDrugs review of children with idiopathic growth hormone deficiency (PMID 18031173) and a 2006 discussion of adult-onset growth hormone insufficiency (PMID 18046908). Neither is a study of trained adults.
The documentation gap is worth restating in the same breath. The certificate for lot 38-01260229, produced by MZ Biolabs on February 7, 2026, reports 99.79% purity and 11.31 mg against a 10 mg label by HPLC-UV-MS. It carries no endotoxin test and no sterility test, and FDA's stated concern for this peptide class is the "risk for immunogenicity" arising from "the potential for aggregation and peptide-related impurities". Scope is a property of that lot. Domestic dispatch does not widen it.
Frequently asked questions
Is sermorelin available legitimately in the United States?
Yes, through compounding on a valid prescription. Sermorelin acetate was a component of an FDA-approved drug product, which is one of the conditions section 503A sets for a bulk substance with no USP monograph. Research suppliers sell it separately under laboratory-use terms, which is a different transaction.
Why does US stock matter more than the price difference?
Because the border affects seizure risk, transit days, cumulative heat exposure and recourse all at once. An imported order that fails usually has no remedy, and the saving on the sticker is small compared with losing the order entirely.
Was sermorelin removed from the US market for safety reasons?
No. The FDA product record carries the Federal Register determination that it was not discontinued or withdrawn for safety or effectiveness reasons. Both Geref applications are simply discontinued, and there is no current US label.
Does research-use labelling mean the compound is prohibited?
No. It means the seller makes no human-use claim and publishes no dosing, because the product carries no current label. It is a statement about the terms of sale rather than about the legal status of the molecule.
Why is sermorelin treated differently from MK-677 in the US?
Because of the regulatory record. Ibutamoren mesylate carries a Category 2 listing under both 503A and 503B, ipamorelin acetate is listed under 503B, and sermorelin is absent from that list entirely. That difference is about documented history, not about claimed effect.
This article is for educational purposes only and is not medical advice. Sermorelin was approved as Geref and is now discontinued, with no current US label; material sold by research suppliers is labeled for laboratory use only and not for human consumption. Speak with a qualified healthcare professional before making any decision involving peptides, injections, or off-label compounds.